Preeclampsia is a disease associated to hypertension during pregnancy. It can cause serious complications in the mother’s health and fetus. It is only solved with the birth.
Echevarne Laboratory has a test which is able to detect an early preeclampsia by a blood test. This test uses two levels of angiogenic markers, sFlt1 and PlGF, which identifies women who will develop preeclampsia. PlGF levels are lower than in normal pregnancies and sFlt1 are higher and increase faster.
PIGF: Pro-angiogenic factor which stimulates the formation of blood vessels in the placenta
sFlt1: Anti-angiogenic factor. Receptor for vascular endothelial growth factor
Ratio between sFlt-1 and PlGF diagnoses preeclampsia before clinical symptoms appear
APPLICATIONS IN CLINICAL PRACTICE:
Improve prediction of preeclampsia
- Improving risk of stratification and management of preeclampsia
- In the first quarter of pregnancy: identification of pregnant women may benefit from prophylaxis (11-13 weeks) or intensive follow-up (20-24 weeks)
- Identify clinical conditions such as HELLP syndrome (hemolysis, elevated transaminases, and decreased platelets) that are not always present with hypertension and proteinuria
- Low levels of PIGF and high levels of sFlt1 can be measured up to five weeks before the appearance of clinical symptoms
- Ratio sFlt1/PIGF has a sensitivity and specificity greater than 95% for the diagnosis of early preeclampsia once established by clinical criteria
- A high rise in the proportion warns of impending birth
- Differential diagnosis between preeclampsia and the worsening of other diseases that can mimic the same condition
- Identification of cases favorable to conservative treatment
- Selection of candidates for future preventive and curative treatments